Development of a high-affinity inhibitor of the prostaglandin transporter

Yuling Chi, Jaeki Min, Jean Francois Jasmin, Michael P. Lisanti, Young Tae Chang, Victor L. Schuster

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prostaglandin E 2 (PGE 2) triggers a vast array of biological signals and physiological events. The prostaglandin transporter (PGT) controls PGE2 influx and is rate-limiting for PGE 2 metabolism and signaling termination. PGT global knockout mice die on postnatal day 1 from patent ductus arteriosus. A high-affinity PGT inhibitor would thus be a powerful tool for studying PGT function in adult animals. Moreover, such an inhibitor could be potentially developed into a therapeutic drug targeting PGT. Based on structure-activity relationship studies that built on recently identified inhibitors of PGT, we obtained N-(2- (2-(2-azidoethoxy)ethoxy)ethyl)-4-((4-((2- (2-(2-benzamidoethoxy) ethoxy)ethyl)amino)-6-((4-hydroxyphenyl)amino)-1,3,5- triazin-2- yl)amino)benzamide (T26A), a competitive inhibitor of PGT, with a K i of 378 nM. T26A seems to be highly selective for PGT, because it neither interacts with a PGT homolog in the organic anion transporter family nor affectsPGE 2 synthesis. In Madin-Darby canine kidney cells stably transfected with PGT, T26A blocked PGE 2 metabolism, resulting in retention of PGE 2 in the extracellular compartment and the negligible appearance of PGE 2 metabolites in the intracellular compartment. Compared with vehicle, T26A injected intravenously into rats effectively doubled the amount of endogenous PGE 2 in the circulation and reduced the level of circulating endogenous PGE 2 metabolites to 50%. Intravenous T26A was also able to slow the metabolism of exogenously injected PGE 2. These results confirm that PGT directly regulates PGE 2 metabolism and demonstrate that a high-affinity inhibitor of PGT can effectively prevent PGE 2 metabolism and prolong the half-life of circulating PGE 2.

Original languageEnglish (US)
Pages (from-to)633-641
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume339
Issue number2
DOIs
StatePublished - Nov 2011

Fingerprint

Prostaglandin Antagonists
Prostaglandins E
Prostaglandins
Organic Anion Transporters
Madin Darby Canine Kidney Cells
Patent Ductus Arteriosus
Drug Delivery Systems
Structure-Activity Relationship
Dinoprostone
Knockout Mice
Half-Life

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Development of a high-affinity inhibitor of the prostaglandin transporter. / Chi, Yuling; Min, Jaeki; Jasmin, Jean Francois; Lisanti, Michael P.; Chang, Young Tae; Schuster, Victor L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 339, No. 2, 11.2011, p. 633-641.

Research output: Contribution to journalArticle

Chi, Yuling ; Min, Jaeki ; Jasmin, Jean Francois ; Lisanti, Michael P. ; Chang, Young Tae ; Schuster, Victor L. / Development of a high-affinity inhibitor of the prostaglandin transporter. In: Journal of Pharmacology and Experimental Therapeutics. 2011 ; Vol. 339, No. 2. pp. 633-641.
@article{272b756a1bed42f8b7700b964112dabb,
title = "Development of a high-affinity inhibitor of the prostaglandin transporter",
abstract = "Prostaglandin E 2 (PGE 2) triggers a vast array of biological signals and physiological events. The prostaglandin transporter (PGT) controls PGE2 influx and is rate-limiting for PGE 2 metabolism and signaling termination. PGT global knockout mice die on postnatal day 1 from patent ductus arteriosus. A high-affinity PGT inhibitor would thus be a powerful tool for studying PGT function in adult animals. Moreover, such an inhibitor could be potentially developed into a therapeutic drug targeting PGT. Based on structure-activity relationship studies that built on recently identified inhibitors of PGT, we obtained N-(2- (2-(2-azidoethoxy)ethoxy)ethyl)-4-((4-((2- (2-(2-benzamidoethoxy) ethoxy)ethyl)amino)-6-((4-hydroxyphenyl)amino)-1,3,5- triazin-2- yl)amino)benzamide (T26A), a competitive inhibitor of PGT, with a K i of 378 nM. T26A seems to be highly selective for PGT, because it neither interacts with a PGT homolog in the organic anion transporter family nor affectsPGE 2 synthesis. In Madin-Darby canine kidney cells stably transfected with PGT, T26A blocked PGE 2 metabolism, resulting in retention of PGE 2 in the extracellular compartment and the negligible appearance of PGE 2 metabolites in the intracellular compartment. Compared with vehicle, T26A injected intravenously into rats effectively doubled the amount of endogenous PGE 2 in the circulation and reduced the level of circulating endogenous PGE 2 metabolites to 50{\%}. Intravenous T26A was also able to slow the metabolism of exogenously injected PGE 2. These results confirm that PGT directly regulates PGE 2 metabolism and demonstrate that a high-affinity inhibitor of PGT can effectively prevent PGE 2 metabolism and prolong the half-life of circulating PGE 2.",
author = "Yuling Chi and Jaeki Min and Jasmin, {Jean Francois} and Lisanti, {Michael P.} and Chang, {Young Tae} and Schuster, {Victor L.}",
year = "2011",
month = "11",
doi = "10.1124/jpet.111.181354",
language = "English (US)",
volume = "339",
pages = "633--641",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Development of a high-affinity inhibitor of the prostaglandin transporter

AU - Chi, Yuling

AU - Min, Jaeki

AU - Jasmin, Jean Francois

AU - Lisanti, Michael P.

AU - Chang, Young Tae

AU - Schuster, Victor L.

PY - 2011/11

Y1 - 2011/11

N2 - Prostaglandin E 2 (PGE 2) triggers a vast array of biological signals and physiological events. The prostaglandin transporter (PGT) controls PGE2 influx and is rate-limiting for PGE 2 metabolism and signaling termination. PGT global knockout mice die on postnatal day 1 from patent ductus arteriosus. A high-affinity PGT inhibitor would thus be a powerful tool for studying PGT function in adult animals. Moreover, such an inhibitor could be potentially developed into a therapeutic drug targeting PGT. Based on structure-activity relationship studies that built on recently identified inhibitors of PGT, we obtained N-(2- (2-(2-azidoethoxy)ethoxy)ethyl)-4-((4-((2- (2-(2-benzamidoethoxy) ethoxy)ethyl)amino)-6-((4-hydroxyphenyl)amino)-1,3,5- triazin-2- yl)amino)benzamide (T26A), a competitive inhibitor of PGT, with a K i of 378 nM. T26A seems to be highly selective for PGT, because it neither interacts with a PGT homolog in the organic anion transporter family nor affectsPGE 2 synthesis. In Madin-Darby canine kidney cells stably transfected with PGT, T26A blocked PGE 2 metabolism, resulting in retention of PGE 2 in the extracellular compartment and the negligible appearance of PGE 2 metabolites in the intracellular compartment. Compared with vehicle, T26A injected intravenously into rats effectively doubled the amount of endogenous PGE 2 in the circulation and reduced the level of circulating endogenous PGE 2 metabolites to 50%. Intravenous T26A was also able to slow the metabolism of exogenously injected PGE 2. These results confirm that PGT directly regulates PGE 2 metabolism and demonstrate that a high-affinity inhibitor of PGT can effectively prevent PGE 2 metabolism and prolong the half-life of circulating PGE 2.

AB - Prostaglandin E 2 (PGE 2) triggers a vast array of biological signals and physiological events. The prostaglandin transporter (PGT) controls PGE2 influx and is rate-limiting for PGE 2 metabolism and signaling termination. PGT global knockout mice die on postnatal day 1 from patent ductus arteriosus. A high-affinity PGT inhibitor would thus be a powerful tool for studying PGT function in adult animals. Moreover, such an inhibitor could be potentially developed into a therapeutic drug targeting PGT. Based on structure-activity relationship studies that built on recently identified inhibitors of PGT, we obtained N-(2- (2-(2-azidoethoxy)ethoxy)ethyl)-4-((4-((2- (2-(2-benzamidoethoxy) ethoxy)ethyl)amino)-6-((4-hydroxyphenyl)amino)-1,3,5- triazin-2- yl)amino)benzamide (T26A), a competitive inhibitor of PGT, with a K i of 378 nM. T26A seems to be highly selective for PGT, because it neither interacts with a PGT homolog in the organic anion transporter family nor affectsPGE 2 synthesis. In Madin-Darby canine kidney cells stably transfected with PGT, T26A blocked PGE 2 metabolism, resulting in retention of PGE 2 in the extracellular compartment and the negligible appearance of PGE 2 metabolites in the intracellular compartment. Compared with vehicle, T26A injected intravenously into rats effectively doubled the amount of endogenous PGE 2 in the circulation and reduced the level of circulating endogenous PGE 2 metabolites to 50%. Intravenous T26A was also able to slow the metabolism of exogenously injected PGE 2. These results confirm that PGT directly regulates PGE 2 metabolism and demonstrate that a high-affinity inhibitor of PGT can effectively prevent PGE 2 metabolism and prolong the half-life of circulating PGE 2.

UR - http://www.scopus.com/inward/record.url?scp=80054775987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054775987&partnerID=8YFLogxK

U2 - 10.1124/jpet.111.181354

DO - 10.1124/jpet.111.181354

M3 - Article

C2 - 21849625

AN - SCOPUS:80054775987

VL - 339

SP - 633

EP - 641

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -